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Abstract
Background: Cancer-testis antigens are among the new promising biomarkers, especially for targeted therapy.
Aberrant and specific expression of these proteins has been reported in some tumor tissues. Also understanding
their differential role in normal and cancer tissues may introduce them as new candidates for biomarker in cancer.
Methods: AKAP3 expression was investigated in 162 tumors, normal adjacent and normal tissues of the breast with
Real-Time PCR. Also the correlation between the gene expression and clinico-pathologic features of the tumors and
treatment regimen was evaluated.
Results: There was an association between lack of AKAP3 expression in tumor tissues and triple negative status
(p=. 03). There was also a correlation between lack of this marker and tumor size (p = .01) and stage (p = .04). Lack
of AKAP3 in normal adjacent tissues was associated with poor prognosis. Kaplan Meier plot demonstrated a
remarkable better 5-year disease free survival in AKAP3 positive normal adjacent group.
Conclusions: It was found that this relationship is originated from the difference in AKAP3 expression, not therapy
distribution between two groups of patients. Thus, it may be a proper biomarker candidate for triple negative
breast cancer patients. Also, testing AKAP3 in normal tissue of the patients may be used to predict the outcome of
the treatment.
Background
Among women, breast cancer is the most prevalent can-
cer and also one of the leading causes of cancer mortal-
ity. Biomarkers are the most useful tools for prevention
and better management of the disease. Although the bio-
marker discovery has led to a great deal of results in
many aspects of cancer, there are still many challenging
issues in this area which cause biomarker discovery to
be still underway. Moreover triple negative breast cancer
(TNBC) as a more aggressive and poor prognosis breast
cancer is still an important clinical challenge.
Cancer-testis antigens (CTA) are among the new
promising biomarkers, especially for targeted therapy
[1]. They are members of a group of proteins which are
normally expressed in testis and to a lesser extent in
ovarian germ cells [2, 3]. Since the aberrant and specific
expression of these biomarkers has been reported in
some tumor tissues, they may act as new candidates for
targeted therapy [4]. Also understanding their differen-
tial role in normal and cancer tissues may emerge new
predictive or prognostic biomarkers. Therefore the study
of the expression pattern of these biomarkers and its re-
lationship to clinical features of the patients are subjects
of great interest.
A-kinase anchoring proteins (AKAP) are a group of
CTA which play important roles in sperm function and
are classified based on their ability of binding to c-AMP
dependent protein kinase A (PKA) II. AKAP encoded
proteins are localized in the fibrous sheath of sperm and
may act as regulators of its motility, capacitation and ac-
rosome reaction [5].
AKAP3 is a member of AKAP proteins that was re-
ported to be expressed in epithelial ovary cancer. AKAP3
expression was found to be a significant predictor of both
overall and progression-free survival in patients with
poorly differentiated ovary tumors [6].
* Correspondence: kmajidzadeh@razi.tums.ac.ir
1Cancer Genetics Department, Breast Cancer Research Center, ACECR, No
146, South Gandhi Ave, Vanak Sq., Tehran, Iran
2Tasnim Biotechnology Research Center (TBRC), School of Medicine, AJA
University of Medical Sciences, Tehran, Iran
Full list of author information is available at the end of the article
© 2015 Esmaeili et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Esmaeili et al. BMC Cancer  (2015) 15:681 
DOI 10.1186/s12885-015-1668-0
In this study, we aimed to determine if there is a spe-
cific expression of AKAP3 in tumor compared to normal
tissue. Based on this specific expression, this marker can
be a candidate to use as prognostic, predictive or even
as a candidate for targeted therapy. To test this potency,
the presence of AKAP3 mRNA was investigated in in-
vasive ductal carcinoma (IDC) of breast comparing to
adjacent normal and normal tissues. Also the correl-
ation between the gene expression and clinico-pathologic




A total of 162 breast tissue samples including 74 tumor,
73 normal adjacent, 15 normal breast tissues were taken
from the Breast Cancer Research Center Biobank
(BCRC-BB) [7]. Two breast cancer cell lines (MCF7 and
T47D) (taken from Avicenna infertility clinic (AIC))
were included in the study. To check the probability of
AKAP3 expression in breast tumor cells, its expression
was checked first in these two cell line then it was
assayed in tumor, normal and normal adjacent tissues
using Normal testis tissue as a positive control. Accord-
ing to the protocols followed by BCRC-BB, after exci-
sional biopsy or surgery the content of cancer cells in
each sample was pathologically checked and immediately
sample tissues were snap-frozen in liquid nitrogen and
stored at −70 °C. BCRC-BB is obliged to ethical guide-
lines and recommendations for biobanks on the storage
and use of human biological samples. Also, all patients
provided written informed consent before entering the
biobank. This study was approved by the Ethics Com-
mittee of the BCRC before conducting the project. The
Clinical and histopathological features of patients along
with treatment regimen were gathered. Patient’s status
was defined based on the occurrence of any event like
recurrence, metastasis or death due to cancer in their
follow-up history. Patients who had these events are cat-
egorized as poor prognosis group. Patients were catego-
rized in treatment subgroups according their treatment
status as follows: CMF (cyclophosphamide, methotrexate
and 5-fluorouracil) regimen and anthracycline and/or
taxane-containing regimen with or without endocrine
therapy and finally endocrine therapy only.
Real-Time PCR
RNA extraction and cDNA synthesis were done as previ-
ously explained [8]. Primers for AKAP3 and Actin Beta
(ACTB) which was designed by Gene Runner v.3.05 and
confirmed with primer express 3.0.are as follows:
AKAP3 F: CAGGACTGGAAAATGGACACCT, AKAP3
R: TTTGTGTGGGTCTCCTGAGTTG. ACTB F: CAGC
AGATGTGGATCAGCAAG, ACTB R: GCATTTGCG
GTGGACGAT
To check the presence of AKAP3 mRNA, Real Time
PCR was carried out using SYBR Green PCR Master
Mix (PrimerDesign Ltd, UK). Primer concentration was
0.5 μM for both genes. ACTB was detected to confirm
cDNA quality. Fluorescent detection was performed
using Applied Biosystems 7500 System. To ensure the
formation of specific amplicon, first the size of the PCR
product was checked on agarose electrophoresis and was
sequenced using Big Dye terminator DNA sequencing
(Applied Biosystems, Foster City, CA) (data not shown),
then each reaction was followed by melting curve ana-
lysis involving heating of the PCR product from 60 to
95 °C. The curve in the specimens was compared with
curve of positive control to recognize specific amplicon
from primer dimer formation. The melt point of 83.4 °C
was defined for AKAP3 amplicon. Reactions with this
melting point were considered positive for AKAP3 expres-
sion. Any amplicon with other melt point was regarded as
nonspecific amplification. Data were analyzed using SDS
software, vers.2.0 (Applied Biosystems).
Data analysis
Patients were categorized based on their type of tumor,
according to ER, PR and Her2/neu status. Moreover
AKAP3 expression was analyzed in each type of tumor,
including triple negative group and the remaining types
including ER/PR +Her2/neu -, ER/PR- Her2/neu + and
ER/PR/ Her2/neu +. Different combinations of these
groups were used for data analysis.
All statistical analyses were performed with the SPSS
statistical software (vers.18). The relationship between the
presence of AKAP3 expression and clinico-pathological
data and treatment regimen were analyzed using nonpara-
metric tests. Patient disease free survival was assessed by
Kaplan-Meier analysis using log-rank tests. The P value of
<0.05 was considered as significant results. All the plots
were performed using Graph Pad Prism 3.02 (GraphPad
Software, San Diego, Calif ).
Results
Study population
Clinico-pathological characteristics of the study popula-
tion are presented in Table 1. The median age of the
samples was 48 (range: 29–87 years). Median duration
of follow up was 35 (1–65 months). The percentage of
patients with stage 1 to 4 is 10, 48, 30 and 12 corres-
pondingly. 31 % of patients had an event like recurrence,
metastasis or death due to cancer in their follow-up his-
tory while 69 % didn’t show any event and 4 patients
had no available event data. ER, PR and Her2/neu posi-
tivity were 44, 35 and 31% respectively. The most fre-
quent treatment subgroup was anthracycline and/or
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taxane-containing regimen with endocrine which was
44% (data not shown).
Expression of AKAP3 mRNA
Two breast cancer cell lines expressed AKAP3 mRNA.
AKAP3 expression was seen in normal testis tissue
which serves as a positive control, 36.5 % of tumors,
43.2 % of normal adjacent and 46.6 % of normal breast
tissues, while Actin Beta was expressed in all the
samples.
The McNemar’s test revealed no difference in distribu-
tion of AKAP3 expression between tumor and normal
adjacent tissues. The relationship between AKAP3 ex-
pression and ER, PR and Her2/neu status was analyzed
in tumor and normal adjacent tissues separately. There
was a significant association between lack of AKAP3
expression in tumor tissues and triple negative status
(p=. 03) and there was no correlation with the remaining
types including ER/PR +Her2/neu -, ER/PR- Her2/neu
+ and ER/PR/ Her2/neu +. AKAP3 negativity is a real
absence of this gene and it is not based on specific cut
point. To check if this difference originates from AKAP3
expression or from treatment regimen, the association
between AKAP3 expression in tumor tissues and treat-
ment regimen was investigated and no association was
seen.
There was a significant association between lack of
AKAP3 in normal adjacent tissue and poor prognosis
(p = .003). It means that patients with AKAP3 expres-
sion in normal adjacent tumor (28/63 of the patients)
were associated with only 4/28 events compared to
an event rate of 13/35 in the AKAP3 negative group.
Kaplan Meier plot demonstrated a remarkable better
survival in AKAP3 positive normal adjacent group,
that was statistically significant in log-rank analysis
(P = .03) (Fig. 1). The follow-up for both groups were
comparable (P = .2). There was not such a relationship
with the AKAP3 expression in tumor tissues (P = .8).
To find if this significance result originated from
triple negative status as a poor prognosis subtype or
it is from lack of AKAP3 expression in normal adja-
cent, we analyzed the relationship of AKAP3 in nor-
mal adjacent tissues and prognosis in the triple
negative group compared to other types. This associ-
ation was not correlated with the triple negative
group. In other words, the relationship between lack
of AKAP3 expression in normal adjacent and poorer
outcome is significantly detectable in the other sub-
types of breast cancer than triple negative breast can-
cer (p = .01). The analysis between AKAP3 expression
in normal adjacent tissues and treatment regimen
didn't show any significant results (Fig. 2). Chi-square
analysis showed a significant relationship between the
expression of AKAP3 in tumor tissues and tumor size
(p=. 01) and stage (p=. 04). Based on these analyses,
AKAP3 expression in tumor tissues was diminished
in tumor size above 2 cm. Also the proportion of pa-
tients in stage one who expressed AKAP3 in their
tumor tissues was more than other stages. Same ana-
lysis with grade, number of positive lymph nodes and
Table 1 Patient’s characteristics and AKAP3 status. Stage grouping
are based on American Joint Committee on Cancer (AJCC),
Estrogen receptor (ER), progesterone receptor (PR), Her2/neu are
based on IHC results. Cut point of positivity is based on American
Society of Clinical Oncology (ASCO) guideline for IHC
Number of patients 74
Age (median/range) — year 48 (29–87) Valid percent
Follow-up (median/range)—month 1 8 (1–38)
ER status (2 missing, n = 74)
Negative 40 55
Positive 32 45
PR (2 missing, n = 74)
Negative 47 65
Positive 25 35
Her2/neu status (2 missing, n = 74)
Negative 50 69
Positive 22 31




Patient status (3 missing, n = 74)
healthy survival 50 70
with events 21 30





Tumor Size (6 missing, n = 74)
<=2 24 35
>2 44 65
AKAP3 Tumor (n = 74)
Negative 47 64
Positive 27 36
AKAP3 Normal adjacent (n = 73)
Negative 40 56
Positive 32 44
Akap3 Normal Breast (n = 15)
Negative 8 54
Positive 7 46
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Figure 1 AKAP3 expression in tumor and normal adjacent tissue of the breast. a-c Represent AKAP3 expression in tumor (AKAP3T) and
clinico-pathological features. Significant results were seen in stage, subtype and tumor size. d-f Show AKAP3 expression in normal adjacent tissue
(AKAP3N) and clinico-pathological features. Significant result was seen in the event which represents prognosis
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the age of diagnosis of the patients did not show any
significant results (Table 2).
Discussion
Looking for genes that are specifically expressed in can-
cer tissues and have a limited expression in normal tis-
sues is one of the most important targets of researchers
in the field of cancer treatment. Among these targets,
CTAs could be a promising option and there are a lot of
researches in this field [1, 2, 7–9]. In this study expres-
sion of AKAP3 were investigated in tumor, normal adja-
cent and normal tissue of the breast in association with
clinical features of the patients.
AKAP3 is classified as one of the members of scaffold
proteins (AKAPs). They are a family of about 50 scaf-
folding proteins which anchor protein kinase A (PKA) II
and other proteins including protein kinases, protein
phosphatases and phosphodiesterases. So they can spe-
cify intracellular locations and restrict the corresponding
enzymatic activities [10, 11]. As a result of multi-protein
complexes which are formed by these anchoring pro-
teins, cAMP signaling is integrated with other pathways
[5]. Such a compartmentalization represents the critical
roles of AKAPs in cellular activities. Accordingly subtle
changes in the AKAPs related pathways or their compo-
nents is an explanation of the development of many dis-
eases, especially cancer [12].
Triple negative breast cancer is still poorly character-
ized at the molecular level and Lack of prognostic
markers and selective targets of therapy make it the
most aggressive type of breast cancer which deserves
more investigation [13, 14]. In the current study AKAP3
expression is deficient significantly in triple negative tu-
mors. CAMP-dependent protein kinase is usually
present in tissues as a mixture of type I and type II iso-
zyme and changing their ratio involved in the oncogenic
process. The PKAII is mostly present in normal tissues,
whereas its isoform PKAI which is not related to AKAPs
is expressed in malignant tissues [15]. Since AKAP3 is a
scaffold for binding of PKAII, lack of AKAP3 expression
which is seen in this study may be due to the absence or
decreased level of PKAII in malignant tissues. Although
this could be the reason of absence of AKAP3 expres-
sion in malignant tissue, we still don’t know whether the
hormone independence status in triple negative tissues
affects this status or not. If this protein have eligibility to
use as prognostic factor in triple negative patient require
further investigation. Based on this study, AKAP3 ex-
pression decreased significantly while tumors increased
in size and stage. This may be due to the association of
PKAII with inhibition of mitogenic signaling and cell
growth [16]. Moreover, since PKA signaling with differ-
ent AKAPs may direct cell toward proliferation or death,
AKAP3 may act as an inhibitor of proliferation signals
[17]. But, further study need to decide about this sugges-
tion because down regulated genes are not always in-
volved in inhibition of proliferation.
Based on the results, the patients with lack of AKAP3
in their normal adjacent tissues represent the poorer
outcome. The analysis between expression of this gene
and different treatment subtypes revealed no significant
results which may show that the significant differences
in patient survival, found in this study, would be origi-
nated from the difference in AKAP3 expression not
therapy distribution between two groups of patients. In
the previous study by Sharma s et al., AKAP3 expression
correlated with poor prognosis in epithelial ovarian can-
cer [6], but its expression was not explored in normal
adjacent tissue. Alteration in gene expression of histo-
logically normal adjacent tissue is a matter of debate. A
number of studies suggested that morphologically nor-
mal tissue adjacent to carcinomas has not undergone
significant gene expression changes when compared to
normal tissue [18]. In contrast, some evidence suggests
Figure 2 Kaplan Meier plot. Kaplan Meier plot of patient survival stratified by AKAP3 expression in tumor (right) and normal adjacent (left) tissues.
Vertical tick marks represent censored patients. Censoring means the total survival time for that patient cannot be accurately determined. Most of
the time occurs when participants either drop out of the study or refuse to participate in the study
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that these tissues represent modifications in molecular
level resembling tumor tissues [19]. These alterations
can reveal the earliest changes leading to tumorigenesis
or may due to the effect of the tumor. In two studies in
prostate cancer, microarray comparison of tumor, nor-
mal adjacent and normal tissue revealed up- regulation
of transcription factors, signal transducers and growth
regulatory genes in tumor and normal adjacent but nor-
mal tissues [20, 21]. In 2006 Schneiders et al., suggested
that the genetic profile of the normal adjacent tissue
may be associated with treatment failure in rectal cancer,
suggesting the importance of the tumor microenviron-
ment in the development of recurrence of rectal tumors
[22]. Since recurrence is a significant clinical problem
for patients with cancer, having the possibility of genetic
assessment in normal material of patients in predicting
the recurrence is of great interest in medical research.
More research on AKAP3 on easily accessible tissues of
Table 2 AKAP3 expression and clinico-pathologic data. Statistical association between clinico-pathologic data and AKAP3 expression
in tumor and normal adjacent tissue
Variable AKAP3 expression p value AKAP3 expression p value
In tumor In normal
Negative no (%) Positive no (%) Negative no (%) Positive no (%)
ER
Negative 27 (67.5) 13 (32.5) 0.4 21 (55.3) 17 (44.7) 0.5
Positive 20 (62.5) 12 (37.5) 17 (53.1) 15 (46.9)
PR
Negative 30 (63.8) 17 (36.2) 0.4 24 (53.3) 21 (46.7) 0.5
Positive 17 (68) 8 (32) 14 (56) 11 (44)
Her2
Negative 34 (68) 16 (32) 0.3 25 (51) 24 (49) 0.2
Positive 13 (59.1) 9 (40.9) 13 (61.9) 8 (38.1)
Tumor Grade
1 3 (50) 3 (50) 0.7 3 (50) 3 (50) 0.9
2 21 (61.8) 13 (38.2) 18 (52.9) 16 (47.1)
3 18 (66.7) 9 (33.3) 14 (56) 11 (44)
Lymph Node
No 15 (68.2) 7 (31.8) 0.7 10 (45.5) 12 (54.5) 0.3
1-3 13 (56.5) 10 (43.5) 11 (47.8) 12 (52.2)
4-9 8 (57.1) 6 (42.9) 9 (75) 3 (25)
>9 7 (70) 3 (30) 6 (60) 4 (40)
Tumor size
≤2cm 10 (41.7) 14 (58.3) 0.01 13 (54.2) 11 (45.8) 0.5
>2 cm 32 (72.7) 12 (27.3) 23 (54.8) 19 (45.2)
Stage
I 1 (14.3) 6 (85.7) 0.04 2 (28.6) 5 (71.4) 0.2
II 22 (66.7) 11 (33.3) 16 (48.5) 17 (51.5)
III 14 (66.7) 7 (33.3) 12 (63.2) 7 (36.8)
IV 6 (75) 2 (25) 6 (75) 2 (25)
Subtype
Triple Negative 20 (80) 5 (20) 0.03 13 (54.2) 11 (45.8) 0.5
Other types 27 (56.3) 21 (43.8) 26 (55.3) 21 (44.7)
Patient status
No event 31 (63.3) 18 (36.7) 0.5 19 (41.3) 27 (58.7) 0.003
With event 14 (66.7) 7 (33.3) 16 (80) 4 (20)
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the patients could help to decide whether it is possible
to use normal material of the patients to predict the out-
come of the treatment.
Conclusion
In conclusion, between the variety of biomarkers candi-
dates, CTAs are promising genes among which AKAPs
draw much attention. Based on the results, AKAP3 may
be a proper candidate for further investigation as a bio-
marker for triple negative status. AKAP3 may act as in-
hibitor of proliferation since it was not expressed in
higher stage and tumor size. Moreover, our findings war-
rant complementary experiments, especially in protein
level to define the value of AKAP3 testing in normal tis-
sue of patients as a marker of response to treatment.
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